Diagnostic performance between in-house and commercial SARS-CoV-2 serological immunoassays including binding-specific antibody and surrogate virus neutralization test (sVNT).
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
02 01 2023
02 01 2023
Historique:
received:
18
09
2022
accepted:
12
12
2022
entrez:
2
1
2023
pubmed:
3
1
2023
medline:
5
1
2023
Statut:
epublish
Résumé
This study aimed to evaluate the correlation between in-house and commercial binding-specific IgG antibodies and between in-house and commercial SARS-CoV-2 surrogate virus neutralization tests (sVNT). Samples from healthcare workers who received vaccines against SARS-CoV-2 were tested for RBD-specific antibody, S-specific antibody, and in-house ELISA, commercial sVNT, and in-house sVNT, against wild-type SARS-CoV-2. Three hundred and five samples were included in the analysis. The correlation between S-specific binding antibodies and in-house ELISA was 0.96 (95% CI 0.96-0.97) and between RBD-specific antibodies and in-house ELISA was 0.96 (95% CI 0.95-0.97). The Cohen's kappa between in-house sVNT and the commercial test was 0.90 (95% CI 0.80, 1.00). If using 90% inhibition of sVNT as the reference standard, the optimal cut-off value of RBD-specific antibodies was 442.7 BAU/mL, the kappa, sensitivity, and specificity being 0.99, 99%, and 100%, respectively. The optimal cut-off value of S-specific antibodies was 1155.9 BAU/mL, the kappa, sensitivity, and specificity being 0.99, 100%, and 99%, respectively. This study demonstrated a very strong correlation between in-house ELISA and 2 commercial assays. There was also a very strong correlation between in-house and commercial SARS-CoV-2 sVNT, a finding of particular interest which will inform future research.
Identifiants
pubmed: 36593231
doi: 10.1038/s41598-022-26202-1
pii: 10.1038/s41598-022-26202-1
pmc: PMC9806819
doi:
Substances chimiques
COVID-19 Vaccines
0
Immunoglobulin G
0
Antibodies, Viral
0
Antibodies, Neutralizing
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
34Informations de copyright
© 2022. The Author(s).
Références
Sci Rep. 2021 Nov 23;11(1):22777
pubmed: 34815503
Stat Med. 2004 Aug 30;23(16):2537-50
pubmed: 15287083
J Clin Epidemiol. 2005 Aug;58(8):859-62
pubmed: 16018921
Cell. 2020 Jun 25;181(7):1489-1501.e15
pubmed: 32473127
Cell. 2020 Nov 12;183(4):996-1012.e19
pubmed: 33010815
Nat Commun. 2021 May 11;12(1):2670
pubmed: 33976165
Nat Biotechnol. 2020 Sep;38(9):1073-1078
pubmed: 32704169
Stat Methods Med Res. 2018 Aug;27(8):2374-2383
pubmed: 28673124
Nat Med. 2021 Jul;27(7):1205-1211
pubmed: 34002089
Nat Rev Immunol. 2021 Aug;21(8):475-484
pubmed: 34211186
Diagnostics (Basel). 2021 Mar 25;11(4):
pubmed: 33806216
Microbiol Spectr. 2022 Feb 23;10(1):e0140221
pubmed: 35196824
Nat Med. 2021 Nov;27(11):2032-2040
pubmed: 34588689
BMC Infect Dis. 2022 May 7;22(1):439
pubmed: 35525973
Int Immunopharmacol. 2021 Nov;100:108095
pubmed: 34619529
Nat Med. 2021 Feb;27(2):270-278
pubmed: 33335323
Cell. 2021 Feb 18;184(4):861-880
pubmed: 33497610
Biochem Med (Zagreb). 2012;22(3):276-82
pubmed: 23092060
Turk J Emerg Med. 2018 Aug 07;18(3):91-93
pubmed: 30191186
BMC Med. 2022 Jan 21;20(1):31
pubmed: 35057798
Science. 2021 Apr 30;:
pubmed: 33931567
Diagn Microbiol Infect Dis. 2021 Apr;99(4):115294
pubmed: 33387896
Trends Immunol. 2020 May;41(5):355-359
pubmed: 32249063
J Clin Lab Anal. 2021 Sep;35(9):e23921
pubmed: 34369009
NPJ Vaccines. 2021 May 13;6(1):74
pubmed: 33986272
Microbiol Spectr. 2021 Dec 22;9(3):e0120221
pubmed: 34817223
Commun Biol. 2021 Jan 29;4(1):129
pubmed: 33514825
Nat Rev Immunol. 2021 Apr;21(4):195-197
pubmed: 33674759
Zhongguo Dang Dai Er Ke Za Zhi. 2021 Mar;23(3):221-228
pubmed: 33691913
Lancet Microbe. 2022 Jan;3(1):e52-e61
pubmed: 34806056
PLoS One. 2020 Oct 6;15(10):e0240076
pubmed: 33022019
J Immunol. 2021 Jun 1;206(11):2566-2582
pubmed: 33911008
Nat Protoc. 2021 Jun;16(6):3114-3140
pubmed: 33893470
Nat Med. 2022 May;28(5):1072-1082
pubmed: 35165453
Science. 2021 Mar 25;:
pubmed: 33766944
Comput Math Methods Med. 2017;2017:3762651
pubmed: 28642804
Proc Natl Acad Sci U S A. 2005 Apr 5;102(14):5108-13
pubmed: 15792998